β-actin-luc - Model 10500

Random Transgenic

β-actin-luc (Model 10500) Random Transgenic Mouse Model
This model has been replaced by an improved model - β-actin-luc - model 11977

Mixed Background

  • Model #
  • Genotype
  • Nomenclature
  • 10500-F
    tg/wt
    B6;FVB-Tyrc-2J Tg(Actb-luc)46Xen
  • 10500-M
    tg/wt
    B6;FVB-Tyrc-2J Tg(Actb-luc)46Xen
  • Carries a 14 kb fragment of the murine β-actin promoter isolated from genomic DNA, a chimeric intron and modified firefly luciferase cDNA (Promega pGL3)
  • Basal expression of the reporter is highest in skeletal muscle, thymus, skin, heart, bone, pancreas, and is detectable in all tissues, including white blood cells
  • The reporter is constitutively expressed and is not significantly inducible
  • Useful as a donor animal for studying the transplantation of various tissue types
  • SNP testing has shown that the strain background is equivalent only to 4-5 backcrosses onto B6 albino, so the background is designated as B6;FVB. Taconic will further backcross onto B6 albino and offer an improved model in the future.

Genetic Background:

B6;FVB Background

Origin:

The β-actin-luc mouse was developed by Caliper Life Sciences. The model was created by microinjecting a transgene containing a fragment of the murine β-actin promoter isolated from genomic DNA, a chimeric intron and modified firefly luciferase cDNA from pGL3. This transgene was microinjected into FVB/N zygotes. The resultant mice from founder line 46 were bred to FVB/NTac mice. The line was backcrossed the equivalent of 4-5 times onto the C57BL/6J-Tyrc-2J and intracrossed to make the coat color mutation homozygous. Taconic received stock from Caliper in 2010, and the line was embryo transfer derived. In the production colony, the line is maintained by mating mice which are wild type to those which are hemizygous for the luciferase transgene.


Availability:

This model has been replaced by an improved model - β-actin-luc - model 11977

Color:

Albino

Species:

Mouse

Initial Publication:

There is no specific publication describing the generation of these mice, but multiple publications exist demonstrating applications using the mice. See reference list.

 

Other publications:

Cheeran MC, Mutnal MB, Hu S, Armien A, Lokensgard JR. (2009) Reduced lymphocyte infiltration during cytomegalovirus brain infection of interleukin-10-deficient mice. J Neurovirol. 15(4):334-42.

Murphy CT, Moloney G, Macsharry J, Haynes A, Faivre E, Quinlan A, McLean PG, Lee K, O'Mahony L, Shanahan F, Melgar S, Nally K. (2010) Technical Advance: Function and efficacy of an {alpha}4-integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis. J Leukoc Biol. 88(6):1271-8.

Murphy CT, Moloney G, Hall LJ, Quinlan A, Faivre E, Casey P, Shanahan F, Melgar S, Nally K. (2010) Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis. Clin Exp Immunol. 162(1):188-96.

Schachtele SJ, Hu S, Little MR, Lokensgard JR. (2010) Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J Neuroinflammation. 7:35.

 



Conditions of Use
Title to the LPTA® Models is not transferred to researcher. Researcher has only the following limited rights to use the LPTA® Models. Researcher may obtain derivatives from the LPTA® Models, consisting of tissues or organs, for their research use, however researcher shall have no right to establish luciferase containing cell lines from such derivatives. Researcher may not breed or propagate the LPTA® Models without the prior express written consent of Taconic. Researcher may not transfer the LPTA® Models or any derivatives to a third party. TACONIC MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED,INCLUDING FOR NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE LPTA® MODELS.

Use of the LPTA® Models may require a license to perform certain methods of non-invasive in vivo imaging of mammals that are covered by patents controlled by Caliper Life Sciences, Inc., including without limitation U.S. Patent Nos. 5,650,135; 6,217,847; 7,198,774; 6,649,143; 6,939,533; 6,916,462; 6,923,951; 6,890,515; and 6,908,605. The purchase of the LPTA® Models does not convey any license rights under such patents. Researcher should contact Caliper Life Sciences, Inc. to obtain license rights to such patents.
Luciferase Expression of Transgenes in β-Actin-luc Mice
Figure 1A: Male and female mice were imaged in the ventral (left) and dorsal (right) regions. High basal luciferase expression was observed in males and females in feet, tail, ear, and mouth, all areas where bare skin is visible. Luciferase expression was observed in male gonads in some animals.

Figure 1B. β-actin-luc tissue expression survey from 2 male and 2 female mice (Fig. 1A). Data are expressed in Relative Light Units (RLU)/mg protein.
Luciferase Expression in Tissue Extracts

Tissue Expression of Luciferase signal

Luciferase expression of the β-actin-luc transgene was examined in extracts of tissue dissected from adult male and female mice from the β-actin-luc LPTA® animal model. Luciferase expression was highest in skeletal muscle, thymus skin, heart, bone, pancreas, and was detectable in all tissues examined including white blood cells (Fig. 1B). The bar graph is plotted with a logarithmic ordinate scale to graphically display all data. The expression data agree with ex vivo study data (not shown) and published work examining constitutive promoter-driven transgene expression.1,2 Luciferase expression was also examined in white blood cells from β-actin-luc mice (Fig. 1C (below)). Whole blood was harvested and spun to enrich for white blood cells. Cells were then serially diluted in a 96-well plate and placed in media containing luciferin substrate.

Luciferase Expression in β-Actin-Luc Circulating White Blood Cells
Figure 1C: Luciferase Expression in β-Actin-Luc Circulating White Blood Cells

Imaging Recommendations

Anesthetize mice prior to injection of luciferin and measurement of luciferase transgene expression. Optimal imaging occurs between 10 and 20 minutes following intraperitoneal injection of luciferin.